Targeting HER2+ breast cancer: The TBK1/IKKε axis

Oncoscience

Volumn 1, Issue 2, 2014, Pages 180-182

  Jiang, Zhe ^a   Liu, JeffC ^a   Chung, Philip E D ^a   Egan, Sean E ^b   Zacksenhaus, Eldad ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Breast cancer; HER2; IKK ; TBK1; Therapy

Indexed keywords

EID: 84905009151     PISSN: None     EISSN: 23314737     Source Type: Journal    
DOI: 10.18632/oncoscience.18     Document Type: Article

References (9)

1. Deng T, Liu JC, Chung PE, Uehling D, Aman A, Joseph B, Ketela T, Jiang Z, Schachter NF, Rottapel R, Egan SE, Al-Awar R, Moffat J and Zacksenhaus E. Cancer Res. 2014; 74(7): 2119-30.
2. Liu JC, Deng T, Lehal RS, Kim J and Zacksenhaus E. Cancer Res. 2007; 67(18): 8671-8681.
3. Liu JC, Voisin V, Bader GD, Deng T, Pusztai L, Symmans WF, Esteva FJ, Egan SE and Zacksenhaus E. Proc Natl Acad Sci U S A. 2012; 109(15): 5832-5837.
4. Shen RR and Hahn WC. Oncogene. 2011; 30(6): 631-641.
5. Mulero MC, Bigas A and Espinosa L. Oncotarget. 2013; 4(10): 1550-1551.
6. Ou YH, Torres M, Ram R, Formstecher E, Roland C, Cheng T, Brekken R, Wurz R, Tasker A, Polverino T, Tan SL and White MA. Mol Cell. 2011; 41(4): 458-470.
7. Wei C, Cao Y, Yang X, Zheng Z, Guan K, Wang Q, Tai Y, Zhang Y, Ma S, Cao Y, Ge X, Xu C, Li J, Yan H, Ling Y, Song T, et al. Proc Natl Acad Sci U S A. 2014; 111(5): E601-610.
8. Yang KM, Jung Y, Lee JM, Kim W, Cho JK, Jeong J and Kim SJ. Cancer Res. 2013; 73(22): 6679-6689.
9. Reilly SM, Chiang SH, Decker SJ, Chang L, Uhm M, Larsen MJ, Rubin JR, Mowers J, White NM, Hochberg I, Downes M, Yu RT, Liddle C, Evans RM, Oh D, Li P, et al. Nat Med. 2013; 19(3): 313-321.